

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non-Small Cell Lung Cancer

Maurice Pérol,¹ Wei Li,³ Nathan A. Pennell,² Geoffrey Liu,⁴ Yuichiro Ohe,⁵ Filippo De Braud,⁶ Misako Nagasaka,⁷ Enriqueta Felip,⁸ Anwen Xiong,³ Yongchang Zhang,⁹ Huijie Fan,¹⁰ Xicheng Wang,¹¹ Bing Yan,¹² Shuanglian Li,¹² Michael Chen,¹² Lyudmila Bazhenova,¹³ Caicun Zhou³

¹Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France; ²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ³Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China; ⁴Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, Canada; ⁵National Cancer Center Hospital, Tokyo, Japan; ⁶University of Milan, Milan, Italy; ⁷University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA, USA; ⁸Vall d'Hebron University Hospital, Barcelona, Spain; ⁹Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; ¹⁰The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ¹¹The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University, Guangzhou, China; ¹²Nuvation Bio, New York, NY, USA; ¹³University of California San Diego Moores Cancer Center, San Diego, CA, USA



Copies of this poster obtained through QR Code are for personal use only and may not be reproduced without permission from the author of this poster.


Objectives

This integrated analysis of the registrational cohorts of patients from the regional TRUST-I and global TRUST-II studies assessed the efficacy and safety of taletrectinib in people living with advanced ROS1+ NSCLC

Background


- Taletrectinib is an oral, selective, CNS-active, next-generation ROS1 TKI with selectivity over TrkB¹⁻³
- Potent against ROS1 and acquired-resistance mutations, such as G2032R
- Clinical exposures at steady state sufficient to inhibit both ROS1 and ROS1^{G2032R}
- Taletrectinib demonstrated high and durable overall responses, intracranial activity, prolonged PFS, activity against G2032R, and had a favorable safety profile in the regional TRUST-I study (NCT04395677)²
- Previously, data from TRUST-II⁴ and TRUST-II⁴ were presented individually; we now present a more mature integrated analysis from the largest efficacy population (N=273) of people living with advanced ROS1+ NSCLC from pivotal studies

Methods




^aOr ≥20 years, as required by local regulations. ^bOne prior ROS1 TKI (crizotinib [C] or entrectinib [E]). ^cThree patients in TRUST-I started taletrectinib 400 mg and of these, 2 escalated to 600 mg.

Results




^aPatients in REP. ^bOverall, 172 (63%) patients from TRUST-I and 101 (37%) from TRUST-II were enrolled. ^cAssessed by an IRC per mRECIST version 1.1.

cORR by IRC




^aThree patients with confirmed BOR as not evaluable are not displayed in the waterfall plot. ^bSix patients with confirmed BOR as not evaluable are not displayed in the waterfall plot. ^cOne patient had a best percentage change of 0 and BOR as SD.

Efficacy in TKI-Naive Patients



^aREP patients with a confirmed objective response.

Efficacy in TKI-Pretreated Patients



^aREP patients with a confirmed objective response.


Conclusions

Integrated analysis from the TRUST-I and TRUST-II studies establishes taletrectinib as a potential best-in-class ROS1 TKI for people living with advanced ROS1+ NSCLC

- High and durable overall response rates were observed in both cohorts
- In TKI-naive patients, median DOR and median PFS were 44.2 months and 45.6 months, respectively
- In TKI-pretreated patients, median DOR and median PFS were 16.6 months and 9.7 months, respectively
- IC responses were robust in both cohorts, and G2032R response rates were high in TKI-pretreated patients
- Response rates were consistent among the subgroups analyzed
- Taletrectinib demonstrated a favorable tolerability and safety profile in people living with advanced ROS1+ NSCLC
- TEAEs were mostly grade 1-2
- Rates of neurologic TEAEs were low (dizziness: 21.1%; dysgeusia: 14.5%), and most were grade 1
- Low incidence of discontinuations (6.5%) due to TEAEs

Overall, taletrectinib demonstrated a favorable benefit risk profile at the recommended phase 2 dose of 600 mg QD

IC-cORR by IRC^a



^aREP patients with measurable brain metastases and a confirmed response. ^bOne patient with confirmed BOR as not evaluable is not displayed in the waterfall plot.

cORR by Subgroup in REP

Subgroup	No. of subjects	No. of responses	cORR (95% CI)
TKI Naive			
Overall	160	142	88.8 (82.80, 93.19)
Region category 1			
Western	21	17	81.0 (58.09, 94.55)
Asian	139	125	89.9 (83.68, 94.38)
Brain metastasis by IRC at baseline (mRECIST v1.1)			
Yes	37	32	86.5 (71.23, 95.46)
No	123	110	89.4 (82.60, 94.25)
Prior chemotherapy			
Yes	32	28	87.5 (71.01, 96.48)
No	128	114	89.1 (82.33, 93.89)
TKI Pretreated			
Overall	113	63	55.8 (46.11, 65.09)
Region category 1			
Western	26	17	65.4 (44.33, 82.79)
Asian	87	46	52.9 (41.87, 63.67)
Brain metastasis by IRC at baseline (mRECIST v1.1)			
Yes	55	31	56.4 (42.32, 69.70)
No	58	32	55.2 (41.54, 68.26)
Prior chemotherapy			
Yes	42	25	59.5 (43.28, 74.37)
No	71	38	53.5 (41.29, 65.45)

Safety

TEAEs in ≥15% of Patients With ROS1+ NSCLC Treated With Taletrectinib 600 mg QD (N=337)^a

TEAE, n (%)	Any grade	Grade 1	Grade 2	Grade 2-3 ^b
Patients with ≥1 TEAE	336 (99.7)	30 (8.9)	132 (39.2)	174 (51.6)
Increased AST	243 (72.1)	161 (47.8)	56 (16.6)	26 (7.7)
Increased ALT	229 (68.0)	135 (40.1)	60 (17.8)	34 (10.1)
Diarrhea	213 (63.2)	168 (49.9)	38 (11.3)	7 (2.1)
Nausea	159 (47.2)	123 (36.5)	31 (9.2)	5 (1.5)
Vomiting	146 (43.3)	114 (33.8)	27 (8.0)	5 (1.5)
Anemia	126 (37.4)	75 (22.3)	39 (11.6)	12 (3.6)
Constipation	71 (21.1)	61 (18.1)	10 (3.0)	0
Dizziness	71 (21.1)	64 (19.0)	6 (1.8)	1 (0.3)
QT prolongation	65 (19.3)	44 (13.1)	9 (2.7)	12 (3.6)
Increased blood creatinine	61 (18.1)	50 (14.8)	11 (3.3)	0
Increased blood bilirubin	59 (17.5)	43 (12.8)	12 (3.6)	4 (1.2)
Increased blood CPK	56 (16.6)	36 (10.7)	13 (3.9)	7 (2.1)
Decreased neutrophil count	56 (16.6)	28 (8.3)	14 (4.2)	14 (4.2)
Decreased appetite	53 (15.7)	38 (11.3)	14 (4.2)	1 (0.3)
Decreased WBC count	53 (15.7)	31 (9.2)	17 (5.0)	5 (1.5)

^aMost grade per patient reported. ^b3 patients reported grade 5 AEs that were possibly treatment-related: hepatic failure, hepatic function abnormal, and pneumonia; n=1 each.

Abbreviations

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BOR, best overall response; C, crizotinib; cORR, confirmed objective response rate; CPK, creatinine phosphokinase; CR, complete response; CNS, central nervous system; DCR, disease control rate; DOR, duration of response; E, entrectinib; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, intracranial; IRC, independent review committee; mRECIST, modified Response Evaluation Criteria in Solid Tumors v1.1; NR, not reached; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors v1.1; REP, response evaluable population; SD, stable disease; TEAE, treatment-emergent adverse event; TrkB, tropomyosin receptor kinase B; TKI, tyrosine kinase inhibitor; WBC, white blood cell.

References

- Nagasaka M, et al. *Future Oncol*. 2023;19(2):123-135.
- Li W, et al. *J Clin Oncol*. 2024;42(22):2660-2670.
- Papadopoulos KP, et al. *Clin Cancer Res*. 2020;26(18):4785-4794.
- Pérol M, et al. *Ann Oncol*. 2023;34(suppl 2):S788-S789.

Acknowledgements

- We would like to thank all patients who participated in this study, the study investigators, and their staff
- This study was sponsored by AnHeart Therapeutics, a wholly owned subsidiary of Nuvation Bio Inc. Writing support was provided by David Jensen, PhD, of Peloton Advantage, LLC, an OPEN Health company, and was funded by Nuvation Bio.